Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
All times are local (Market data is delayed by at least 15 minutes).

medigene ag (MDG) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIGENE AG (MDG)

Related News

No related news articles were found.

medigene ag (MDG) Related Businessweek News

No Related Businessweek News Found

medigene ag (MDG) Details

Medigene AG, a biotechnology company, researches and develops drugs to treat cancer and autoimmune diseases in Europe, Asia, and the United States. The company operates in two segments, Marketed Products and Drug Candidates. The Marketed Products segment offers Veregen, an ointment used to treat external genital warts. The Drug Candidates segment’s pipeline products include EndoTAG-1, a drug candidate that has completed two Phase II clinical trials for the treatment of pancreatic and breast cancer; and RhuDex, which is in Phase II clinical trial for the oral treatment of autoimmune diseases. It is also developing DC vaccines that are in Phase II clinical trials for treating prostate cancer; and Phase I/II clinical trials for the treatment of acute myeloid leukaemia. In addition, this segment is developing T cell receptor-(TCR) modified T cells, which is in pre-clinical trial for the treatment of advanced cancer; anti-TCR monoclonal antibodies that is in pre-clinical trial to treat T cell-mediated diseases, such as T cell leukaemia or auto-immune diseases; and adeno-associated virus-like particles, a technology platform for prophylactic and therapeutic vaccines, which is in pre-clinical trials. It has strategic partnership with Syncore Biotechnologies Ltd. The company was founded in 1994 and is headquartered in Martinsried, Germany.

65 Employees
Last Reported Date: 03/25/15
Founded in 1994

medigene ag (MDG) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: €563.0K
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €390.0K
Compensation as of Fiscal Year 2013.

medigene ag (MDG) Key Developments

MediGene AG, 2014 Earnings Call, Mar 25, 2015

MediGene AG, 2014 Earnings Call, Mar 25, 2015

Medigene AG Reports Consolidated Earnings Results for the Year 2014; Provides Earnings Guidance for the Full Year of 2015

Medigene AG reported consolidated earnings results for the year 2014. For the year, the company reported total revenue of EUR 13.784 million compared to EUR 7.592 million a year ago. Negative operating result was EUR 2.881 million compared to EUR 9.021 million a year ago. Net negative result was EUR 5.757 million compared to EUR 10.282 million a year ago. EBITDA loss was EUR 2.071 million compared to EUR 8.270 million a year ago. In 2015, the company expects a double-digit percentage increase in Veregen(R) royalties based on the assumptions made by Medigene's partners. In spite of reduced milestone payments, total revenue for Veregen(R) is planned to remain stable in 2015. Due to increased investment in Medigene's innovation the anticipated EBITDA loss will increase to EUR 11 million to EUR 13 million in 2015.

Medigene AG Reports Preliminary Earnings Results for the Year 2014

Medigene AG reported preliminary earnings results for the year 2014. For the year, the company reported total revenue rose by 82% to EUR 13.8 million compared to EUR 7.6 million a year ago. Revenue from the marketed drug Veregen(R) increased by 23% to EUR 5.2 million compared to EUR 4.2 million a year ago. Other operating income includes EUR 2.7 million for a milestone achieved at the end of 2014 for the partnered drug candidate EndoTAG(R)-1 which was not included in the company's financial guidance. The company reduced its EBITDA loss by 75% to EUR 2.1 million compared to EUR 8.3 million a year ago. The net loss was reduced by 44% to EUR 5.8 million compared to EUR 10.3 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDG:GR €0.00 EUR 0.00

MDG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $304.76 USD +1.20
Hemispherx Biopharma Inc $0.23 USD +0.0044
Merck & Co Inc $58.34 USD +0.59
View Industry Companies
 

Industry Analysis

MDG

Industry Average

Valuation MDG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.2x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIGENE AG, please visit www.medigene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.